Human Genome Sciences Completes Enrollment for Lymphostat-B Phase 2 Clinical Study
Posted Sep 07 2008 2:11am
Human Genome Sciences, Inc., of Rockville, Maryland, has announced completion of enrollment for the second of two phase two clinical studies of Lymphostat-B, a potential new treatment for lupus. "The LFA congratulates officials of Human Genome Sciences, Inc. for passing this important mile marker," said Sandra C. Raymond, President & CEO of the Lupus Foundation of America. "Millions of people worldwide suffering from lupus have waited nearly five decades for safe, effective and tolerable treatments to manage lupus."
"We look forward to reviewing the results of these trials when they are completed in 2009, as well as data from trials of other promising treatments in the near-term pipeline," said Raymond. "This is an exciting time in lupus drug development and we are encouraged that physicians will soon have new tools to managing this devastating and life-threatening disease."
"We look forward to reviewing the results of these trials when they are completed in 2009, as well as data from trials of other promising treatments in the near-term pipeline," said Raymond. "This is an exciting time in lupus drug development and we are encouraged that physicians will soon have new tools to managing this devastating and life-threatening disease."
Read the Human Genome Sciences Press Release.